Seeking Alpha

Shares of Bio-Reference Laboratories (BRLI -9.5%) get hammered, despite its FQ3 beating on its...

Shares of Bio-Reference Laboratories (BRLI -9.5%) get hammered, despite its FQ3 beating on its bottom line earlier today. Net earnings rose 25% Y/Y, as the clinical-testing company's streak of double-digit revenue growth continued, but investors appear to be taking advantage of near 52-week highs to lock in profits as sales growth shows signs of stagnating.
Comments (1)
  • dowjobber
    , contributor
    Comments (153) | Send Message
     
    "as sales growth shows signs of stagnating"
    But sales were up 16.4%! So, maybe it was a
    miss by the analysts' sales estimates or patients
    decided to take long weekends and go to the beach.
    I didn't see any big upside surprises in revenues
    being issued by competitors.
    24 Sep 2012, 06:19 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|